A Peptide-Based Magnetic Chemiluminescence Enzyme Immunoassay for Serological Diagnosis of Coronavirus Disease 2019.

Xue-fei Cai,Juan Chen,Jie-li Hu,Quan-xin Long,Hai-jun Deng,Ping Liu,Kai Fan,Pu Liao,Bei-zhong Liu,Gui-cheng Wu,Yao-kai Chen,Zhi-jie Li,Kun Wang,Xiao-li Zhang,Wen-guang Tian,Jiang-lin Xiang,Hong-xin Du,Jing Wang,Yuan Hu,Ni Tang,Yong Lin,Ji-hua Ren,Lu-yi Huang,Jie Wei,Chun-yang Gan,Yan-meng Chen,Qing-zhu Gao,A-mei Chen,Chang-long He,Dao-Xin Wang,Peng Hu,Fa-Chun Zhou,Ai-long Huang,De-qiang Wang
DOI: https://doi.org/10.1093/infdis/jiaa243
2020-01-01
Abstract:BACKGROUND:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel β-coronavirus, causes severe pneumonia and has spread throughout the globe rapidly. The disease associated with SARS-CoV-2 infection is named coronavirus disease 2019 (COVID-19). To date, real-time reverse-transcription polymerase chain reaction (RT-PCR) is the only test able to confirm this infection. However, the accuracy of RT-PCR depends on several factors; variations in these factors might significantly lower the sensitivity of detection.METHODS:In this study, we developed a peptide-based luminescent immunoassay that detected immunoglobulin (Ig)G and IgM. The assay cutoff value was determined by evaluating the sera from healthy and infected patients for pathogens other than SARS-CoV-2.RESULTS:To evaluate assay performance, we detected IgG and IgM in the sera from confirmed patients. The positive rate of IgG and IgM was 71.4% and 57.2%, respectively.CONCLUSIONS:Therefore, combining our immunoassay with real-time RT-PCR might enhance the diagnostic accuracy of COVID-19.
What problem does this paper attempt to address?